Whan In Pharm Co.,Ltd. (KRX:016580)
11,400
+60 (0.53%)
At close: Oct 31, 2025
Whan In Pharm Revenue
Whan In Pharm had revenue of 64.14B KRW in the quarter ending June 30, 2025, with 0.81% growth. This brings the company's revenue in the last twelve months to 258.70B, up 6.70% year-over-year. In the year 2024, Whan In Pharm had annual revenue of 259.60B with 12.68% growth.
Revenue (ttm)
258.70B
Revenue Growth
+6.70%
P/S Ratio
0.68
Revenue / Employee
427.61M
Employees
409
Market Cap
176.03B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 259.60B | 29.20B | 12.68% |
| Dec 31, 2023 | 230.39B | 31.46B | 15.81% |
| Dec 31, 2022 | 198.93B | 21.16B | 11.90% |
| Dec 31, 2021 | 177.78B | 6.07B | 3.54% |
| Dec 31, 2020 | 171.71B | 12.53B | 7.87% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2012 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2011 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2010 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.03T |
| Celltrion | 3.75T |
| Yuhan | 2.17T |
| SK Biopharmaceuticals | 620.28B |
| PharmaResearch | 449.81B |
| Sam Chun Dang Pharm. | 215.10B |
| ALTEOGEN | 158.06B |
| LigaChem Biosciences | 148.28B |